GlassScriptPhysician profile
Shannan Mccann
NPI 1710968227
$1,967.64
in general payments reported to CMS, 2019-2025
19 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $1,385 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.39 |
| Education | $199.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $279.78 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $237.55 | 2024-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $209.58 | 2024 | Sotyktu |
| Krystal Biotech INC | $193.97 | 2023-2025 | Vyjuvek |
| Abbvie INC. | $162.09 | 2023-2024 | |
| Genzyme Corporation | $131.31 | 2024 | |
| Revance Therapeutics, INC. | $129.69 | 2024 | Daxi |
| Lilly USA, LLC | $110.01 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $100.62 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $76.76 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $70.46 | 2024 | |
| Leo Pharma INC. | $62.68 | 2025 | Adbry, Anzupgo |
| Ucb, INC. | $44.28 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $41.55 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $34.79 | 2025 | Nemluvio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $27.86 | 2025 | Vtama |
| Biofrontera INC. | $20.70 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Pfizer INC. | $18.02 | 2024 | |
| Fidia Pharma USA INC. | $15.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannan Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.